tiprankstipranks
Arch Therapeutics (ARTH)
OTHER OTC:ARTH
Holding ARTH?
Track your performance easily

Arch Therapeutics (ARTH) Income Statement

162 Followers

Arch Therapeutics Income Statement

Last quarter (Q ), Arch Therapeutics's total revenue was $30.91K, an increase of 85.62% from the same quarter last year. In Q, Arch Therapeutics's net income was $-6.38M. See Arch Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Sep 23Sep 22Sep 21Sep 20Sep 19
Total Revenue
$ 121.94K$ 75.72K$ 15.65K$ 11.56K--
Cost of Revenue
$ 84.77K$ 78.16K$ 51.49K$ 26.28K--
Gross Profit
$ 37.17K$ -2.44K$ -35.84K$ -14.72K--
Operating Expense
$ 4.44M$ 5.12M$ 5.67M$ 6.39M$ 5.35M$ 6.37M
Operating Income
$ -4.41M$ -5.04M$ -5.71M$ -6.38M$ -5.35M$ -6.37M
Net Non Operating Interest Income Expense
$ -2.61M$ -3.10M$ -567.05K$ -150.53K$ -18.53K-
Other Income Expense
-$ 1.16M$ 1.00M$ -287.17K--
Pretax Income
$ -6.19M$ -6.98M$ -5.28M$ -6.24M$ -5.37M$ -6.37M
Tax Provision
-----$ 0.00
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -12.36M$ -6.98M$ -5.28M$ -6.24M$ -4.69M$ -6.37M
Basic EPS
$ -3.76$ -2.27$ -4.00$ -6.00$ -4.00-
Diluted EPS
$ -3.76$ -2.27$ -4.00$ -6.00$ -4.00$ -6.00
Basic Average Shares
$ 14.93M$ 3.07M$ 1.20M$ 1.10M$ 940.26K$ 831.70K
Diluted Average Shares
$ 14.93M$ 3.07M$ 1.20M$ 1.10M$ 940.26K$ 862.88K
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 4.51M$ 5.12M$ 5.72M$ 6.41M$ 5.35M$ 6.37M
Net Income From Continuing And Discontinued Operation
$ -11.63M$ -6.98M$ -5.28M$ -6.24M$ -4.69M$ -6.37M
Normalized Income
$ -3.67M--$ -4.93M--
Interest Expense
------
EBIT
$ -9.85M$ -3.89M$ -4.71M$ -6.09M$ -4.67M$ -6.37M
EBITDA
$ -9.85M$ -3.88M$ -4.71M$ -6.09M$ -4.67M$ -6.36M
Currency in USD

Arch Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis